SEC Comment Letter 0000000000-23-011157 to Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, Inc.
Date: Oct. 12, 2023 · CIK: 0001279704 · Accession: 0000000000-23-011157
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274880
Letter
United States securities and exchange commission logo October 12, 2023 James Caruso President and Chief Executive Officer Cellectar Biosciences, Inc. 100 Campus Drive Florham Park, New Jersey 07932 Re:Cellectar Biosciences, Inc. Registration Statement on Form S-3 Filed October 5, 2023 File No. 333-274880 Dear James Caruso: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Istvan Hajdu, Esq.
Show Raw Text
United States securities and exchange commission logo
October 12, 2023
James Caruso
President and Chief Executive Officer
Cellectar Biosciences, Inc.
100 Campus Drive
Florham Park, New Jersey 07932
Re:Cellectar Biosciences, Inc.
Registration Statement on Form S-3
Filed October 5, 2023
File No. 333-274880
Dear James Caruso:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Istvan Hajdu, Esq.